It has not received marketing authorisation from the MHRA or EMA and is not available as a licensed medicine in the UK
The company does most of its assessment via online questionnaires
Heres commentary from Lily management: There's no doubt in my mind, Geoff in five years, as I said, we're going to have a lot more data and we're going to see these drugs as foundational medical treatment for many chronic diseases, and with outcomes to hard outcomes data that moves the cost curve in populations. And eventually the Venn diagram of seniors who have obesity or overweight and other conditions, diabetes, of course already we have access in many plans there, but we'll be adding to that pie
Different operations carry varying levels of risk and require different recovery periods before these medications can be safely reintroduced
There is no reason to expect retatrutide will be different
If you think you may be eligible for Foundayo or another GLP-1 medication, ask your doctor for more guidance.